Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Aerocrine
Moxis Prosonix |
| gptkbp:CEO |
gptkb:Steve_Harris
gptkb:Ian_Johnson Jonathan Emms |
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:focus |
respiratory diseases
|
| gptkbp:founded |
2006
|
| gptkbp:founder |
gptkb:Steve_Harris
Charles Swingland |
| gptkbp:headquarters_location |
gptkb:Oxford
|
| https://www.w3.org/2000/01/rdf-schema#label |
Circassia Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listed_on_FTSE |
gptkb:FTSE_SmallCap_Index
|
| gptkbp:notableProduct |
NIOX VERO
|
| gptkbp:product |
NIOX
NIOX MINO NIOX VERO |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
allergy diagnostics
asthma diagnosis |
| gptkbp:stockExchange |
gptkb:London_Stock_Exchange
|
| gptkbp:stockSymbol |
CIR
|
| gptkbp:website |
https://www.circassia.com/
|
| gptkbp:bfsParent |
gptkb:Tudorza
|
| gptkbp:bfsLayer |
7
|